Axsome Therapeutics (AXSM) R&D Day 2025 summary

Pipeline overview and program updates

• Portfolio includes 10 indications across psychiatry and neurology, targeting high unmet needs such as depression, Alzheimer's agitation, smoking cessation, ADHD, binge eating disorder, sleep apnea, narcolepsy, migraine, fibromyalgia, and shift work disorder.

• Three differentiated marketed products and a pipeline with potential for seven new FDA approvals through 2028, aiming for over $16 billion in annual peak sales.

• Issued patents extend to the early 2040s, supporting long-term value creation.

Clinical trial data and development milestones

• Auvelity, a rapid-acting oral NMDA receptor antagonist for MDD, has treated 190,000 new patients and is tracking to $400M annual run rate; peak sales projected at $1–3B.

• AXS-05 for Alzheimer's agitation completed three positive registrational trials; sNDA submission planned this quarter, with peak sales potential over $1.5B.

• Sunosi showed significant efficacy in ADHD and MDD with excessive daytime sleepiness in phase III trials, with rapid onset and robust symptom improvement.

• AXS-12 for narcolepsy demonstrated rapid, robust, and sustained reduction in cataplexy and improvement in sleepiness and cognition in phase III studies; NDA submission expected in Q3.

• AXS-14 (esreboxetine) for fibromyalgia showed significant pain, fatigue, and functional improvements in phase II/III trials, with a favorable tolerability profile.

• Symbravo (meloxicam-rizatriptan) for migraine achieved primary endpoints in two phase III trials, showing rapid and sustained pain freedom with low side effects.

• Ongoing phase III trial of Sunosi in binge eating disorder, with promising tolerability and mechanistic rationale.

R&D strategy and innovation priorities

• Focus on novel mechanisms of action and precision-based approaches for underserved CNS conditions.

• Emphasis on first-in-class or best-in-class therapies, leveraging clinical, operational, and regulatory innovation.